Acute pancreatitis following sleeve gastrectomy with transit bipartition: A case report
Diabetic Medicine · 2026-07 · 43 (7)
DOI: 10.1111/dme.70326 ↗Kurz gefasst
Fallbericht in der Zeitschrift Diabetic Medicine, online erschienen am 20.04.2026. Verfasst von Yanqing Jiang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Center for Obesity & Metabolic Diseases, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. Hauptthemen laut MEDLINE: Gastrectomy, Pancreatitis, Diabetes Mellitus, Type 2, Obesity, Morbid. Die Arbeit nennt 24 Literaturangaben. Gefördert von: the National Natural Science Foundation of China, Sichuan Provincial Natural Science Foundation for Distinguished Young Scholars, Northern Sichuan Medical College Clinical School·Affiliated Hospital Scientific Research Development Plan Project.
Abstract (Originalsprache)
Introduction
Sleeve gastrectomy with transit bipartition (SG‐TB) is an emerging metabolic and bariatric surgery (MBS) procedure for obesity and type 2 diabetes. Acute pancreatitis (AP) is a rare complication of other metabolic and bariatric surgery (MBS) procedures (incidence: 0.27%–3.6%), including Roux‐en‐Y Gastric Bypass (RYGB) and occurs after other MBS procedures such as Roux‐en‐Y Gastric Bypass (RYGB) and standard Laparoscopic Sleeve Gastrectomy (LSG), while no AP cases following SG‐TB have been reported to date. Case Presentation We describe a 41‐year‐old female patient with obesity and type 2 diabetes (BMI 30.6 kg/m 2 ) who developed AP on the 3rd day after an uncomplicated laparoscopic SG‐TB. She presented with epigastric pain radiating to the back, mild elevation of serum amylase and lipase and magnetic resonance imaging findings consistent with the diagnosis of mild AP according to the 2012 Revised Atlanta Criteria.
Discussion
The patient had moderately elevated preoperative triglycerides (5.0 mmol/L), which was below the classical threshold of 11.3 mmol/L for hypertriglyceridemia‐induced AP, thus serving as a background risk factor for the onset, with no other definite etiological factors. Conservative treatment resolved symptoms, pancreatic enzyme levels normalized on the 7th postoperative day, and she was discharged uneventfully.
Conclusion
This case highlights that AP should be included in the differential diagnosis of patients with abdominal pain in the early postoperative period after SG‐TB. Biliogastric reflux‐induced pancreatic duct hypertension following gastrojejunal anastomosis in SG‐TB and iatrogenic mechanical/thermal injury may be the main pathogenic mechanisms, with the patient's metabolic status acting as a synergistic factor for early‐onset AP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Obesity & Metabolic Diseases, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Gastroenterology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
ORCID-Profile: Yuan Zhang
Förderung
- the National Natural Science Foundation of China
- Sichuan Provincial Natural Science Foundation for Distinguished Young Scholars
- Northern Sichuan Medical College Clinical School·Affiliated Hospital Scientific Research Development Plan Project
- National Natural Science Foundation of China
Zitieren
APA
Jiang, Y., Pang, X., Zhang, Z., Xie, S., Yang, H., He, M., & Zhang, Y. (2026). Acute pancreatitis following sleeve gastrectomy with transit bipartition: A case report. Diabetic Medicine, 43(7). https://doi.org/10.1111/dme.70326
Vancouver
Jiang Y, Pang X, Zhang Z, Xie S, Yang H, He M, et al. Acute pancreatitis following sleeve gastrectomy with transit bipartition: A case report. Diabetic Medicine. 2026;43(7). doi:10.1111/dme.70326
BibTeX
@article{Jiang2026,
author = {Jiang, Yanqing and Pang, Xiaotian and Zhang, Zhongyang and Xie, Sijun and Yang, Hao and He, Ming and Zhang, Yuan},
title = {Acute pancreatitis following sleeve gastrectomy with transit bipartition: A case report},
journal = {Diabetic Medicine},
year = {2026},
volume = {43},
number = {7},
doi = {10.1111/dme.70326}
}
EUVIMED